MX2016017081A - Tratamiento de hipertrigliceridemia grave. - Google Patents

Tratamiento de hipertrigliceridemia grave.

Info

Publication number
MX2016017081A
MX2016017081A MX2016017081A MX2016017081A MX2016017081A MX 2016017081 A MX2016017081 A MX 2016017081A MX 2016017081 A MX2016017081 A MX 2016017081A MX 2016017081 A MX2016017081 A MX 2016017081A MX 2016017081 A MX2016017081 A MX 2016017081A
Authority
MX
Mexico
Prior art keywords
treatment
hypertrigliceridemia
serious
mbx
type
Prior art date
Application number
MX2016017081A
Other languages
English (en)
Spanish (es)
Inventor
A Mcwherter Charles
L Martin Robert
Boudes Pol
Jung Choi Yun-
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of MX2016017081A publication Critical patent/MX2016017081A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
MX2016017081A 2014-06-26 2015-06-25 Tratamiento de hipertrigliceridemia grave. MX2016017081A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017444P 2014-06-26 2014-06-26
PCT/US2015/037596 WO2015200580A1 (en) 2014-06-26 2015-06-25 Treatment of severe hypertriglyceridemia

Publications (1)

Publication Number Publication Date
MX2016017081A true MX2016017081A (es) 2017-05-01

Family

ID=53511030

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016017081A MX2016017081A (es) 2014-06-26 2015-06-25 Tratamiento de hipertrigliceridemia grave.

Country Status (16)

Country Link
US (1) US20150374649A1 (OSRAM)
EP (1) EP3160458A1 (OSRAM)
JP (1) JP2017519028A (OSRAM)
KR (1) KR20170020514A (OSRAM)
CN (1) CN106470675A (OSRAM)
AU (1) AU2015279905A1 (OSRAM)
BR (1) BR112016028918A2 (OSRAM)
CA (1) CA2951280A1 (OSRAM)
CL (1) CL2016003290A1 (OSRAM)
EA (1) EA201790091A1 (OSRAM)
HK (1) HK1231380A1 (OSRAM)
IL (1) IL249757A0 (OSRAM)
MX (1) MX2016017081A (OSRAM)
PH (1) PH12016502415A1 (OSRAM)
SG (1) SG11201610243YA (OSRAM)
WO (1) WO2015200580A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN106163508A (zh) 2014-04-11 2016-11-23 西玛贝医药公司 Nafld和nash的治疗
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN111741753A (zh) * 2017-12-21 2020-10-02 兴和株式会社 治疗高甘油三酯血症的方法
WO2021097027A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of alcoholic liver disease
US20210145775A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of intestinal barrier dysfunction and associated diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1667964T3 (pl) 2003-09-19 2010-01-29 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
KR20130073884A (ko) * 2010-03-30 2013-07-03 노파르티스 아게 Ｄｇａｔ1 억제제의 용도

Also Published As

Publication number Publication date
JP2017519028A (ja) 2017-07-13
PH12016502415A1 (en) 2017-02-27
EA201790091A1 (ru) 2017-07-31
CL2016003290A1 (es) 2017-09-08
WO2015200580A1 (en) 2015-12-30
EP3160458A1 (en) 2017-05-03
IL249757A0 (en) 2017-02-28
BR112016028918A2 (pt) 2017-08-22
HK1231380A1 (zh) 2017-12-22
CN106470675A (zh) 2017-03-01
AU2015279905A1 (en) 2017-02-02
SG11201610243YA (en) 2017-01-27
CA2951280A1 (en) 2015-12-30
US20150374649A1 (en) 2015-12-31
KR20170020514A (ko) 2017-02-22

Similar Documents

Publication Publication Date Title
IL278150A (en) A transgenic bacterium for the treatment of diseases related to hyperammonemia
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
MX2016017081A (es) Tratamiento de hipertrigliceridemia grave.
EP3527125C0 (en) CATHETER WITH HIGH DENSITY ELECTRODE TIP ARRAY
HUE040315T2 (hu) Beültethetõ elektróda elrendezés
MA43968A (fr) Thérapie génique pour traiter la mucopolysaccharidose de type i
ZA201703779B (en) Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
CL2016002971A1 (es) Combinación.
DK3162402T3 (da) Næsespraydyse til anvendelse i medicinsk sprøjte
NZ760790A (en) Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
IL260684B (en) Treatment for modulating gut microbiota
DK3229840T3 (da) 3,5-dihydroxy-4-isopropyl-trans-stilben til anvendelse i topisk behandling af akne
IL243044A0 (en) Electrodes for intracardiac catheters that are not sensitive to the far field
FR3016371B1 (fr) Levures modifiees pour utiliser le dioxyde de carbone
SG11201705401YA (en) Methods to improve cell therapy
AU363946S (en) Catheter gripper aid
MX367478B (es) Tratamiento de enfermedades colestasicas intrahepaticas.
IL246052A0 (en) Biomedical electrode having low oxygen content
MA47847A (fr) Thérapie génique pour traiter la mucopolysaccharidose de type i
IL251013A0 (en) Implantable electrode
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
IL237705B (en) Placement of electrodes near the heart
LT3229790T (lt) Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme
PT3188778T (pt) Injetor tipo caneta
MX2016015255A (es) Analogos de omega-3.